Pharma R&D Execs Offer Extravagant Expectations for AI But Few Proof Points
As the excitement around generative AI sweeps across the globe, biopharma R&D groups (like most everyone else) are actively trying to figure out how to... Read More
Your Edge In Biotech.
About David Shaywitz
David Shaywitz, MD PhD is a contributing writer for Timmerman Report.
Focus: the transformational opportunities and implementation challenges presented by emerging technologies in healthcare, biomedical discovery, and biopharmaceutical development, from NGS and cell therapies to digital biomarkers and the meaningful application of AI. Co-author (with Lisa Suennen): Tech Tonics: Can Passionate Entrepreneurs Heal Healthcare With Technology? (Hyperink Press, 2014).
Background: physician-scientist+management consultant, experience in drug development, strategic and commercial planning, tech+health.
Job: I am the founder of Astounding HealthTech, an advisory firm focused on the intersection of biopharma and health technology. Previously, I was Senior Partner, Takeda Ventures, Inc. (corporate/strategic VC focused on early-stage life science), and retain equity interest in DNAnexus from previous Chief Medical Officer role.
Other: I maintain a relationship with the Department of Biomedical Informatics, Harvard Medical School; I am also an Adjunct Scholar, American Enterprise Institute. Twitter: @DShaywitz (broadcast only; I do not engage on the platform). Views=my own, and may not represent the views of any organization with which I’m affiliated. For additional info, please see my personal website here.
Latest Contributions
Big, If True: Opportunities and Obstacles Facing AI (Plus: Summer Reading)
Today, we’ll begin with a consideration of the promise for AI some experts see in healthcare and biopharma. Next, we’ll look at some of the... Read More
Biopharma Innovation – Beyond The Breathless Headlines
Biopharma relies on innovation to stay in business. Success depends on our collective ability to discover, develop, and deliver new products that cure or meaningfully... Read More
Tech, Pharma, and the Uneven Distribution of the AI-Enabled Future
The worlds of technology and entrepreneurship are captivated by recent advances in generative AI and large language models (LLMs). The arrival of ChatGPT, developed by... Read More
New Book Contemplates How Generative AI Will Serve Man
In 1935, Astounding Science — the premier science fiction magazine of the day, and perhaps ever — published “Proxima Centauri.” It was a short story... Read More
Welcome to the AI Irruption
Biopharma, like the rest of the world, appears to be on the threshold of profound, technology-induced change. Incredible advances in artificial intelligence, manifested most recently... Read More
The Success of Your Tech Deployment Depends On A Role You’ve Probably Never Heard Of
The success or failure of many technology platforms — including in particular health tech platforms — rests with a largely obscure role of outsized importance:... Read More
Grand Défi Ou Goulot D’étranglement Ultime: A French Pharma Tackles Data Science
Most biopharma companies have started down the path of digital transformation – a fundamental overhaul of everything they do for the digital age. It’s not... Read More